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Human telomerase reverse transcriptase (hTERT) plays a critical role in the pathogenesis 
of human malignancies. Overexpression of hTERT is essential in controlling the propa-
gation of cancer cells. The CpG island located at hTERT promoter region is subjected 
to methylation modification in human cancer. In this perspective article, we discussed 
the diagnostic value of methylated hTERT in human cancers. The definitive diagnosis of 
most solid tumors is based on histological and immunohistochemical features. Under 
certain circumstances, however, the use of methylated hTERT might be useful in over-
coming the limitation of the conventional methods. Methylated hTERT showed a good 
diagnostic power in discriminating cancer from benign or normal tissues. Nevertheless, 
differences in detection method, methylation site, cancer type, and histological subtype 
of cancer make it difficult to evaluate the actual diagnostic accuracy of methylated hTERT. 
Therefore, we performed subgroup analysis to assess the effects of these factors on 
the diagnostic efficiency of methylated hTERT. We demonstrated that quantitative MSP 
(qMSP) assay offers the highest discriminative power between normal and cancer in 
comparison with different detection methods. In addition, the methylated sites selected 
by different studies had an impact on the detection performance. Moreover, the diagnos-
tic power of methylated hTERT was affected by cancer type and histological subtype. 
In conclusion, the existing evidence demonstrated that methylated hTERT is effective in 
cancer detection. Detailed profiling of the methylation sites to local the common meth-
ylation hotspot across human cancers is warranted to maximize the diagnostic value of 
methylated hTERT in cancer detection.
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inTrODUcTiOn
Cancer is a leading cause of death, accounting for about 14.6% 
of all human deaths (1). Effective medical intervention could 
only be achieved if the cancerous tissue is identified in advance. 
Molecular screening with biomarkers is now recognized as an 
efficient means in early cancer detection. Biomarkers of which 
expression changes have close linkage with the progression of 
cancer phenotype are adopted as an indicator of cancers.
Human telomerase reverse transcriptase (hTERT) activation 
is one of the universal and hallmark changes in cancer progres-
sion. Telomerase is the enzyme responsible for maintaining 
chromosomal endings during cell replication. Telomerase 
activation could lead to uncontrolled proliferation and immor-
talization through inhibition of replicative senescence (2, 3). 
Most mature normal cells silence the telomerase and their 
telomerase expression remains low (4). The telomerase activ-
ity is controlled directly by the transcript quantity of hTERT 
gene. Hence, increased hTERT transcript level is an indication 
of cancer cells and reflects the proliferative propensity accord-
ingly. Clinically, high hTERT level in the cancerous tissue 
is associated with the poor outcome in a number of human 
cancers (5–8).
The gene encoding hTERT is regulated by multiple mecha-
nisms. Activation of hTERT transcription requires the coopera-
tion between multiple regulatory proteins. The promoter region 
of hTERT gene is CpG rich and harbors distinct CpG islands. 
The cytosine of CpG dinucleotides in the hTERT CpG islands 
is susceptible to methylation modification. Methylated CpG 
islands are usually observed in silenced genes as the aberrant 
addition of methyl group has a negative impact on transcrip-
tion initiation. Furthermore, the methylated sequence allows 
the binding of specific transcription suppressors (9, 10). By 
contrast, methylated hTERT promoter has a positive impact 
on its activation because methylation prevents the binding of 
CTCF repressor (11). The methylated promoter DNA allows 
the binding of specific activators and regulatory proteins (e.g., 
c-Myc, Sp1) that regulate hTERT transcription directly (12). 
This feature is cancer specific and is absent in most of the hTERT 
gene in the normal somatic cells (13, 14). Hence, the presence of 
methylated hTERT DNA is a potential indicator for the presence 
of cancer cells.
In comparison with other forms of cancer biomarker, 
methylated gene is advantageous for the high cancer specific-
ity. Aberrant DNA methylation is a covalent modification. The 
diagnostic performance of methylated DNA however varies in a 
gene-by-gene and cancer-specific manner. Not all the methylated 
CpG sites/island can lead to the expression activation of hTERT 
gene. For example, methylation of the E-box in hTERT promoter 
will lead to a weak transcription activation as the interaction 
between C-Myc and E-box was reduced due to the presence of 
methylated moiety (12). Thus, selection between different hTERT 
methylation sites will affect the resulting diagnostic accuracy. At 
present, the use of hTERT DNA as cancer biomarker remains 
controversial as the diagnostic performance varies depending on 
the methylated loci (13, 15). In addition, studies across different 
cancer types examining different hTERT hotspot make it difficult 
to comprehend and evaluate the actual diagnostic accuracy of 
hTERT for cancer detection.
In the current study, we first performed a systematic review 
on the methylated hTERT hotspots in human malignancies. 
Furthermore, meta-analysis was used to evaluate the diagnostic 
performance of hTERT in cancer detection.
MeThYlaTeD hTerT shOWeD a gOOD 
DiagnOsTic POWer in DiscriMinaTing 
cancer FrOM Benign Or nOrMal 
TissUes
Systematic search from PubMed was performed using the key 
terms included “cancer,” “carcinoma,” “tumor,” “neoplasm,” 
“methylation,” “hypermethylation,” “hypomethylation,” “dem-
ethylation,” “TERT,” and “telomerase reverse transcriptase.” In 
total, 290 articles were identified from PubMed search (Figure 
S1 in Supplementary Material). According to our selection 
criteria, we excluded 278 records due to language (n =  9), no 
full-texts (n = 45), review article (n = 35), and irrelevant articles 
(n = 189). Subsequently, the remaining 12 relevant studies with 
full text were assessed. The pooled sensitivity (Se), specificity 
(Sp), and diagnostic odds ratio (DOR) were calculated using 
MetaDiSc software (Version 1.4) (16). Oikonomou et al. (17) were 
excluded due to the fact that the study population is duplicated 
by Iliopoulos et  al. (18). Only studies focused on hTERT core 
regulatory promoter (−1876 to +335) relative to translation start 
site ATG were included (19). Studies by Iliopoulos et  al. were 
excluded as the examined hTERT methylation site was out of 
our scope (18). Finally, our systematic search yielded 10 stud-
ies (20–29). Table S1 in Supplementary Material displayed the 
detailed characteristics of each study. The primers and probes 
used for quantitative MSP (qMSP) assay in different studies were 
listed in Table S3 in Supplementary Materials. The studies quality 
was evaluated using the revised Quality Assessment for Studies 
of Diagnostic Accuracy tool (QUADAS-2), and the results were 
listed in Table S2 in Supplementary Material (30).
For the diagnostic value of methylated hTERT in distinguish-
ing cancer from normal, 7 studies with 543 samples were included 
in this meta-analysis. The pooled sensitivity and specificity 
of methylated hTERT were 0.67 (95%CI, 0.62–0.73) and 0.89 
(95% CI, 0.84–0.93), respectively (Figures 1A,B). The DOR was 
24.71 (95% CI, 7.39–82.63). STATA (Version 12, STATA Crop., 
USA) was used to generate the Fagan plot and likelihood ratio 
scattergram. The pooled positive likelihood ratio (PLR) and 
negative likelihood ratio (NLR) were 8 and 0.24, respectively 
(Figure 1C). As indicated by the pooled PLR value of the seven 
studies, patients with cancer have an eightfold higher chance 
of being methylated hTERT positive in comparison with non-
cancer controls. The pooled NLR value of 0.24 indicates that the 
probability of having cancer is 24% when methylated hTERT was 
negative. The summary likelihood matrix point was located in 
the right lower quadrant (PLR < 10 and NLR > 0.1) (Figure 1D), 
indicating that methylated hTERT is neither useful for confirm-
ing the presence of cancer nor useful as an exclusion indicator. In 
addition, the summary receiver operation characteristic (SROC) 
FigUre 1 | Diagnostic value of methylated hTerT for distinguishing cancer from normal. Forest plot of sensitivity (a) and specificity (B) of methylated 
hTERT for discriminating cancer from normal. (c) Fagan plot displaying post-test probability. (D) Likelihood ratio scattergram for confirmation and exclusion. 
(e) SROC curve for diagnostic accuracy. (F) Funnel plot with superimposed regression line for testing publication bias.
December 2015 | Volume 5 | Article 2963
Gao et al. Diagnostic Value of Methylated hTERT
Frontiers in Oncology | www.frontiersin.org
curve was generated based on sensitivity and specificity of each 
study. The area under the curve (AUC) of SROC curve was 0.90 
(SE = 0.05) (Figure 1E). Publication bias was examined by Deek’s 
funnel plot asymmetry test. No publication bias was observed 
among the selected studies (p = 0.32) (Figure 1F). Heterogeneity 
was assessed by I2 statistic. If I2 value was lower than 50%, the 
study was considered as homogeneous and Mantel–Haenszel 
model was applied. If I2 value was higher than 50%, the study 
was regarded as high heterogeneity and the Dersimonian–Laird 
model was adopted instead. Heterogeneity was observed in both 
sensitivity and specificity of methylated hTERT (Figures 1A,B). 
Threshold evaluation was used to examine the heterogeneity in 
diagnostic tests (16). Threshold effect was evaluated by calculat-
ing Spearman correlation coefficient between logit of sensitivity 
and logit of 1-specificity. The Spearman correlation coefficient of 
logit of sensitivity and logit of 1-specificity of methylated hTERT 
was 0.54 (p = 0.21), indicating that there is no heterogeneity from 
threshold effect.
For the diagnostic performance of methylated hTERT in 
discriminating cancer from benign tissue, the pooled sensitivity 
and specificity were 0.57 (95% CI, 0.49–0.65) and 0.81 (95% 
CI, 0.75–0.86), respectively (Figures  S2A,B in Supplementary 
Material). The DOR was 19.54 (95% CI, 9.53–40.07). The pooled 
PLR and NLR were 10 and 0.59, respectively (Figure S2C in 
Supplementary Material). The summary likelihood matrix 
point was located in the right upper quadrant (PLR >  10 and 
NLR > 0.1) (Figure S2D in Supplementary Material). The AUC of 
SROC curve was 0.88 (SE = 0.03) (Figure S2E in Supplementary 
Material). A p value of 0.14 from Deek’s funnel plot asymmetry 
test suggested no publication bias among studies (Figure S2F in 
Supplementary Material). Heterogeneity was noticed in sensitiv-
ity and specificity (Figures  S2A,B in Supplementary Material). 
Threshold effect was not a source of heterogeneity (Spearman 
correlation coefficient = 0.60, p = 0.40).
Methylated hTERT has a good diagnostic power in discrimi-
nating cancer from normal tissues (DOR: 24.71 and AUC: 0.9). 
The DOR is the ratio of the odds of a true-positive to the odds 
of a false-positive. The value of DOR ranges from 0 to infinity. 
Higher value indicates better discriminatory performance. The 
AUC from the ROC curve is an indicator of diagnostic accuracy 
(AUC > 0.97: excellent accuracy, 0.93–0.96: very good, 0.75–0.92: 
good) (31). The diagnostic accuracy, however, is weaker for dis-
criminating cancer tissues from benign tissues (DOR: 19.54 and 
AUC: 0.88). The diagnostic power is lowest to differentiate benign 
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and normal tissues (DOR: 3.24 and AUC: 0.57). The definitive 
diagnosis of most solid tumor is based on histological and immu-
nohistochemical features. Under certain circumstances, however, 
the use of molecular markers might be useful in overcoming the 
limitation of the conventional methods. For example, fine needle 
aspirate cytology (FNAC) is a major methods used in salivary 
gland tumor diagnosis. It is difficult, however, to distinguish 
patients with carcinoma ex pleomorphic adenoma (Ca ex PSA) 
from benign pleomorphic salivary adenomas (PSA) through 
cytological examination on the aspirate (27). Although FNAC 
has a high diagnostic accuracy for histologically high-grade Ca 
ex PSA, its diagnostic efficiency decreases in low-grade Ca ex 
PSA. Methylated TERT is only present in the Ca ex PSA and is 
undetectable in benign PSA. Thus, the use of methylated TERT 
as adjuvant marker may provide clinical subtype information for 
personalized management of this disease (27).
eFFecTs OF DeTecTiOn MeThODs On 
The DiagnOsTic eFFiciencY OF 
MeThYlaTeD hTerT
Different methods were employed to evaluate the methylation 
status of the hTERT promoter. Six studies used qMSP assay (20, 
22, 23, 25–27). Other detection methods, including methylation-
sensitive dot blot assay (MS-DBA), 3D microarray, methylation-
sensitive single-strand conformation analysis (MS-SSCA), and 
MS-PCR, were employed by the remaining four studies.
For qMSP assay, the pooled sensitivity and specificity were 0.67 
(95% CI, 0.61–0.73) and 0.96 (95% CI, 0.93–0.98), respectively, 
for distinguishing cancer from normal tissues (Figures  S3A,B 
in Supplementary Material). The DOR from studies using 
qMSP assay was 80.86 (95% CI, 31.01–210.86) (Figure S3C in 
Supplementary Material). The value is remarkably higher than 
studies using non-qMSP assays (range: 2.37–17.5) as detection 
mean (Table 1). AUC from studies using qMSP assay (0.97) was 
obviously higher in comparison with the non-qMSP studies 
(range: 0.58–0.85) (Table 1).
These results indicated that different detection methods 
affected the diagnostic efficiency of methylated hTERT. Among 
all the reported methods used in detecting methylated hTERT, 
qMSP assay demonstrated the highest diagnostic accuracy in 
comparison with other detection methods (as evidenced by the 
DOR and AUC values). As the studies employing non-qMSP 
methods (such as MS-DBA and MS-SSCA) only contain a few 
cases and the number of similar studies remains very limiting, 
further comparative studies at a larger scale are essential to affirm 
the performance of qMSP. An AUC value of 0.97 revealed that 
the diagnostic accuracy of methylated hTERT examination using 
qMSP assay is excellent in discriminating cancer from normal 
tissues (31).
DiFFerenTial DiagnOsTic POWer OF 
DiFFerenT qMsP PriMer PrOBe seTs
Among the six studies using qMSP to detect methylated hTERT, 
different primer probe sets were adopted (Table S3 and Figure S4 
in Supplementary Material). For discrimination between cancer 
and normal, primers and probe set flanking −540/−440 yielded 
the highest diagnostic accuracy as evidenced by the highest value 
of DOR (329.67) and AUC (0.96); for distinguishing cancer from 
benign tissue, primer probe set flanking −383/−295 exhibited the 
highest diagnostic efficiency with highest value of DOR (24.40) 
(Table 1).
Different primer probe sets used in the qMSP assays affect the 
diagnostic performance of methylated hTERT. This could possi-
bly be because of the different consequent events associated with 
the methylation of distinct sites of the hTERT promoter. Primers 
with amplicon located at −540/−440 and −383/−295 displayed 
a higher diagnostic accuracy. The promoter region −540/−440 
contains activator protein 2 (AP2) and nuclear factor 1 (NF1)-
binding sites, while promoter region −383/−295 harbors Ikaros 
2 (IK2), AP2 and activator protein 4 (AP4)-binding sites (32). 
The promoter −380/−280 also contained IK2-binding sites. AP2, 
NF1, and AP4 are transcription factors that could activate hTERT 
transcription (33). It has been reported that methylation at AP2-
binding sites suppressed the binding of AP-2 (34). These results 
indicated that methylation at specific binding site could alter the 
binding with its transcription factors, leading to positive regula-
tion of hTERT gene expression. Nevertheless, the regulatory ele-
ments that are essential for the regulation of hTERT gene and the 
diagnostic efficacy of methylated hTERT need to be delineated by 
functional experiments such as in vitro methylation assay.
The DiagnOsTic PerFOrMance OF 
MeThYlaTeD hTerT in VariOUs 
cancers
Two studies investigated the diagnostic value of methylated 
hTERT in both cervical cancer and lung cancer. Only one study 
was available for each of the other cancer types. High variations 
in DOR values (ranged from 1.75 to 329.67) and the AUC values 
(ranged from 0.52 to 0.96) were observed between different 
cancer types (Table  1). Given that the diagnostic accuracy of 
methylated TERT might vary in the histological subtype of each 
cancer type, we intended to stratify each cancer type depending 
on the histological or molecular subtypes and evaluate the perfor-
mance difference of methylated hTERT. Among the 10 included 
studies, only Wang et al. (27) provided histological information 
for subsequent subgroup analysis. Accordingly, their lung cancer 
cohorts could be stratified into two groups: adenocarcinoma and 
squamous cell carcinoma of which, methylated hTERT had a 
remarkably higher value in sensitivity, DOR, and AUC in lung 
squamous cell carcinoma in comparison with adenocarcinoma 
(Table 1).
cOnclUsiOn
Our meta-analysis reveals that methylated hTERT displays 
diagnostic efficacy in cancer detection and qMSP assay exhibits 
the highest discriminative power between normal and cancer 
tissues. Nevertheless, one major limitation of the current study 
is that the sample size of single study is small. The performance 
TaBle 1 | Diagnostic value of methylated hTerT for cancer, benign and normal.
group no. of studies sample size sensitivity (95% ci) specificity (95% ci) Diagnostic Or (95% ci) aUc (se)
Overall
Cancer vs. normal 7 543 0.67 (0.62−0.73) 0.89 (0.84–0.93) 24.71 (7.39–82.63) 0.90 (0.05)
Cancer vs. benign 4 356 0.57 (0.49–0.65) 0.81 (0.75–0.86) 19.54 (9.53–40.07) 0.88 (0.03)
Benign vs. normal 1 202 0.23 (0.16–0.31) 0.92 (0.81–0.97) 3.24 (1.20–8.77) 0.57 (0.04)
Detection methods
qMSP
Cancer vs. normal 3 409 0.67 (0.61–0.73) 0.96 (0.93–0.98) 80.86 (31.01–210.86) 0.97 (0.02)
MS-DBA
Cancer vs. normal 1 12 0.70 (0.35–0.93) 1.00 (0.16–1.00) 10.71 (0.40–287.83) 0.85 (0.12)
MS-PCR
Cancer vs. normal 1 60 0.90 (0.73–0.98) 0.53 (0.34–0.72) 10.29 (2.56–41.37) 0.72 (0.07)
MS-SSCA
Cancer vs. normal 1 22 0.91 (0.59–1.00) 0.64 (0.31–0.89) 17.50 (1.60–191.89) 0.77 (0.11)
3D microarray
Cancer vs. normal 1 40 0.32 (0.16–0.52) 0.83 (0.52–0.98) 2.37 (0.43–13.13) 0.58 (0.10)
Methylation sites (amplicon location)
(−383/−295)
Cancer vs. normal 1 128 0.90 (0.80–0.96) 0.92 (0.81–0.97) 95.66 (28.69–318.94) 0.91 (0.03)
Cancer vs. benign 2 255 0.89 (0.80–0.94) 0.76 (0.69–0.82) 24.40 (11.60–51.31) NA
(−380/−280)
Cancer vs. normal 1 248 0.54 (0.45–0.62) 0.98 (0.94–1.00) 62.70 (14.88–264.09) 0.76 (0.03)
Cancer vs. benign 1 59 0.13 (0.04–0.30) 1.00 (0.88–1.00) 9.33 (0.48–181.51) 0.57 (0.08)
(−540/−440)
Cancer vs. normal 1 33 0.92 (0.62–1.00) 1.00 (0.84–1.00) 329.67 (12.41–8758.83) 0.96 (0.05)
(−346/−273)
Cancer vs. benign 1 42 0.04 (0.00–0.19) 1.00 (0.78–1.00) 1.75 (0.07–45.77) 0.52 (0.09)
cancer type
Cervical cancer
Cancer vs. normal 1 128 0.90 (0.80–0.96) 0.92 (0.81–0.97) 95.66 (28.69–318.94) 0.91 (0.03)
Cancer vs. benign 2 255 0.89 (0.80–0.94) 0.76 (0.69–0.82) 24.40 (11.60–51.31) NA
Lung cancer
Cancer vs. normal 2 288 0.50 (0.42–0.58) 0.97 (0.92–0.99) 12.59 (0.47–340.18) NA
Leptomeningeal metastases
Cancer vs. normal 1 33 0.92 (0.62–1.00) 1.00 (0.84–1.00) 329.67 (12.41–8758.83) 0.96 (0.05)
Colorectal cancer
Cancer vs. Normal 1 22 0.91 (0.59–1.00) 0.64 (0.31–0.89) 17.50 (1.60–191.89) 0.77 (0.11)
Salivary glands carcinoma
Cancer vs. benign 1 59 0.13 (0.04–0.30) 1.00 (0.88–1.00) 9.33 (0.48–181.51) 0.57 (0.08)
Pancreatic cancer
Cancer vs. normal 1 60 0.90 (0.73–0.98) 0.53 (0.34–0.72) 10.29 (2.56–41.37) 0.72 (0.07)
Mesothelioma
Cancer vs. benign 1 42 0.04 (0.00–0.19) 1.00 (0.78–1.00) 1.75 (0.07–45.77) 0.52 (0.09)
Esophageal adenocarcinoma
Cancer vs. normal 1 12 0.70 (0.35–0.93) 1.00 (0.16–1.00) 10.71 (0.40–287.83) 0.85 (0.12)
histological subtype of lung cancer
Adenocarcinoma
Cancer vs. normal 1 27 0.33 (0.12–0.62) 0.83 (0.52–0.98) 2.50 (0.39–16.05) 0.58 (0.11)
Squamous cell carcinoma
Cancer vs. normal 1 19 0.43 (0.10–0.82) 0.83 (0.52–0.98) 3.75 (0.44–31.62) 0.63 (0.14)
qMSP, quantitative methylation-specific PCR; MS-SSCA, methylation-sensitive single-strand conformation analysis; MS-PCR, methylation-specific PCR; MS-DBA, methylation-
sensitive dot blot assay.
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of methylated hTERT as a diagnostic biomarker is highly varying 
relying on the correct selection of methylation hotspots. In order 
to use methylated hTERT as a universal diagnostic or screening 
marker, detail methylation profiling is warranted to define the 
common hTERT methylation hotspots in order to maximize the 
performance of the methylated hTERT as a biomarker in cancer 
detection.
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